Ortec International, a company focused on development and commercialization of products applicable to regenerative medicine and stem cell therapy, June 1 announced that it has received notification from the U.S. patent office that the claims of its patent application on "Novel Haptotactic Peptides," related to its Haptides technology platform, have been allowed. The patent incorporating these claims is expected to be issued by the end of this year. Ortec International (http://www.efcg.net/NewsRelease.asp?NewsID=1248)
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
MHRA Recalls Digital Pregnancy Tests
The recall affected one lot involving 58,000 tests distributed in the UK.Â
Miami Pharmacy Owner Admits to Submitting Over $8 Million in Fraudulent Medicare Claims
The plea followed an investigation by the Justice Department’s Medicare Fraud Strike Force.